December 2nd 2025
The Priority Review decision is based on phase 3 results showing consistent SBP reductions across uncontrolled and treatment-resistant hypertension subgroups.
A Future of Beta-Blockers “Plus” to Treat Hypertension?
May 21st 2013More about the current move away from beta-blocker therapy for hypertension as discussed by speakers at the 2013 ASH annual meeting. Following are some more of the key points, including a discussion of so-called beta-blockers "plus."
Residual Cardiovascular Risks: Don’t Forget Kidney and Vascular Disease
February 28th 2013Typical interventions in persons without CKD are essential. SHARP and TNT have added to our knowledge. Aggressive cholesterol lowering (probably also affecting LDL particle number as well as traditional measures of LDL) seems to afford better outcomes by lessening residual risk in those with chronic kidney disease.
Medical News You May Have Missed (Week of Jan. 14)
January 16th 2013The FDA requires reductions in recommended doses of zolpidem; update on the flu; new BP goals for patients with diabetes; selective use of D-Dimer for suspected DVT; new food safety standards. . . here: 5 quick summaries of medical news headlines with links out to original sources.